Fig. 8: E2F1 activates AURKB expression directly. | Cell Death & Disease

Fig. 8: E2F1 activates AURKB expression directly.

From: AURKB/CDC37 complex promotes clear cell renal cell carcinoma progression via phosphorylating MYC and constituting an AURKB/E2F1-positive feedforward loop

Fig. 8: E2F1 activates AURKB expression directly.

A AURKB mRNA levels in 786-O and CAKI-1 cells with E2F1 knockdown were detected by qRT-PCR. B Schematic diagram of primer design for ChIP-qRT-PCR in the binding site between E2F1 and the promoter region of AURKB. C The binding relationship between E2F1 and the promoter region of AURKB was verified by ChIP-qRT-PCR and agarose gel electrophoresis. D The binding sequence of E2F1 on AURKB predicted by JASPAR was subcloned into the pGL3 promoter luciferase vector. E Luciferase assays were performed in HEK-293 cells co-transfected with siNC/siE2F1-2 and AURKB promoter. F, G MTT and colony formation assays were performed to determine the impact of cell viability treated with NC+ Ctrl, NC + Over-AURKB, siE2F1-2+Ctrl, siE2F1-2+Over-AURKB in ccRCC cells. H, I Transwell and wound‐healing analysis represented the migration and metastasis capacity of ccRCC cells co‐transfected with NC + Ctrl, NC + Over-AURKB, siE2F1-2 + Ctrl, siE2F1-2 + Over-AURKB. J The schematic illustrates that CDC37 and AURKB complexes directly phosphorylate MYC, enhance MYC stability and transcriptional activity, promote Rb phosphorylation and E2F1 release, and in turn activate the transcription of AURKB, forming an AURKB/E2F1 positive feedforward loop that promotes ccRCC progression. *p < 0.05, **p < 0.01, ***p < 0.001.

Back to article page